Pivotal bioVenture Increases Stake in Trevi Therapeutics

Pivotal bioVenture Partners Investment Advisor increased its stake in Trevi Therapeutics (NASDAQ:TRVI) by acquiring 296,944 shares during the first quarter of 2026 for an estimated $3.32 million. The fund now holds a total position valued at $18.54 million, representing 6.6% of its reportable assets under management as of March 31, 2026.

By Sara Appino, The Motley Fool Wed, June 3, 2026 at 5:04 PM GMT+3 4 min read · Yahoo Finance · June 3, 2026, 14:04 UTC

Tickers: $TRVI

Topics: biotech SEC filing stock purchase

Read the full article at Yahoo Finance

More World news

Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC
Acurx Pharmaceuticals Reports Q3 2026 Financial Results and Initiates PATHFINDER Trial Enrollment Motley Fool · November 12, 2026, 16:54 UTC
Fermi Inc. Reports Q3 2026 Net Loss of $141.6 Million Amid Infrastructure Expansion Motley Fool · November 12, 2026, 16:54 UTC
Google Wallet Introduces Digital Home Key Support via Aliro Standard The Verge · November 12, 2026, 16:56 UTC
Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC